BOSTON (Standard&Poor's) Feb. 12, 2013--Standard&Poor's Ratings Services today assigned Montreal-based pharmaceutical company Valeant Pharmaceuticals International Inc.'s proposed $2.3 billion term loans B ($1 billion series C and $1.3 billion series D) its 'BBB-' issue-level rating, with a recovery rating of '1', reflecting our expectation for very high (90%-100%) recovery in the event of a payment default. This is a repricing of the existing series C and series D term loans B. All terms, including the maturity dates of Dec. 11, 2019, and Feb. 13, 2019, respectively, are unchanged. The rating on Montreal-based Valeant Pharmaceuticals International Inc. reflects our belief that the company has an "aggressive" financial risk profile. At Sept. 30, 2012, adjusted leverage (pro forma
